Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma.
apoptosis
biliary tract cancers
gemcitabine resistance
intrahepatic cholangiocarcinoma (iCCA)
paclitaxel
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
09
2021
accepted:
24
01
2022
entrez:
7
3
2022
pubmed:
8
3
2022
medline:
8
3
2022
Statut:
epublish
Résumé
The treatment of unresectable cholangiocarcinoma (CCA) is limited by the development of resistance to conventional first-line chemotherapy based on gemcitabine (GEM). In addition, a prior treatment with GEM frequently induces cross-resistance to other drugs employed in the second-line. Paclitaxel (PTX) is now emerging as an alternative option for the management of advanced/metastatic CCA. In the present work, we evaluate the antitumor activity of PTX in preclinical models of multidrug-resistant intrahepatic cholangiocarcinoma (iCCA).
Identifiants
pubmed: 35251961
doi: 10.3389/fonc.2022.771418
pmc: PMC8891641
doi:
Types de publication
Journal Article
Langues
eng
Pagination
771418Informations de copyright
Copyright © 2022 Massa, Peraldo-Neia, Vita, Varamo, Basiricò, Raggi, Bernabei, Erriquez, Sarotto, Leone, Marchiò, Cavalloni and Aglietta.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Liver Int. 2019 May;39(5):914-923
pubmed: 30716200
Cancer Res. 2016 Aug 15;76(16):4775-84
pubmed: 27328733
Nat Rev Clin Oncol. 2018 Feb;15(2):95-111
pubmed: 28994423
Cancers (Basel). 2021 Apr 23;13(9):
pubmed: 33922695
Ann Oncol. 2014 Feb;25(2):391-8
pubmed: 24351397
Eur J Cancer. 2013 Jan;49(2):329-35
pubmed: 22947649
Int J Oncol. 2015 Oct;47(4):1293-302
pubmed: 26252371
JAMA Oncol. 2018 Dec 1;4(12):1707-1712
pubmed: 30178032
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Ann Oncol. 2014 Dec;25(12):2328-2338
pubmed: 24769639
Tumour Biol. 2016 Mar;37(3):4041-52
pubmed: 26486326
Adv Biol Regul. 2018 May;68:77-87
pubmed: 29221990
Br J Cancer. 1993 Dec;68(6):1104-9
pubmed: 7903152
Cancers (Basel). 2019 Apr 11;11(4):
pubmed: 30979003
Oncol Lett. 2013 Oct;6(4):915-920
pubmed: 24137436
BMC Cancer. 2010 Nov 18;10:631
pubmed: 21087480
Int J Mol Sci. 2017 Aug 09;18(8):
pubmed: 28792473
Mol Clin Oncol. 2017 May;6(5):753-757
pubmed: 28529750
JAMA Oncol. 2019 Jun 1;5(6):824-830
pubmed: 30998813
Oncol Lett. 2018 Jul;16(1):566-572
pubmed: 29963132
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Ther Adv Med Oncol. 2019 May 10;11:1758835919841233
pubmed: 31205498
Oncol Rep. 2018 Apr;39(4):1984-1990
pubmed: 29393478
Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561-5
pubmed: 6103535
Cancer Chemother Pharmacol. 2015 Oct;76(4):699-712
pubmed: 26231955
Int J Mol Sci. 2017 Dec 01;18(12):
pubmed: 29194401
Invest New Drugs. 2018 Dec;36(6):1093-1102
pubmed: 30324343
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Br J Cancer. 2017 Feb 28;116(5):561-567
pubmed: 28081540
Cancer Discov. 2017 Sep;7(9):943-962
pubmed: 28818953
Anticancer Res. 2017 Mar;37(3):1467-1473
pubmed: 28314319
Nature. 1979 Feb 22;277(5698):665-7
pubmed: 423966
Asia Pac J Clin Oncol. 2021 Jun 28;:
pubmed: 34180586
Sci Rep. 2017 Aug 23;7(1):9170
pubmed: 28835684
Lancet Oncol. 2015 Sep;16(9):1090-1098
pubmed: 26254683
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Biomaterials. 2015;53:763-74
pubmed: 25890771